The Universal

Flu Vaccine
Multi-Season
Multi-Strain
Flu Vaccine
CORPORATE PRESENTATION
JUNE 2018
 2

SAFE HARBOR STATEMENT

This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction.

All statements in this communication, other than those relating to historical facts, are "forward-looking statements" within the meaning of the United States
Private Litigation Reform Act of 1995. You can identify forward-looking statements by terms including ‘‘anticipates,’’ ‘‘believes,’’ ‘‘could,’’ ‘‘estimates,’’
‘‘expects,’’ ‘‘intends,’’ ‘‘may,’’ ‘‘plans,’’ ‘‘potential,’’ ‘‘predicts,’’ ‘‘projects,’’ ‘‘should,’’ ‘‘will,’’ ‘‘would,’’ and similar expressions intended to identify forward-
looking statements. These forward-looking statements relate to our business and financial performance and condition, as well as our plans, strategies,
objectives and expectations for our business, operations and financial performance and condition. However, these forward-looking statements are not
guarantees of future performance and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control,
uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results to differ materially
from our expectations include, among others: the risk that drug development involves a lengthy and expensive process with uncertain outcome; BiondVax's
ability to successfully develop and commercialize its vaccine; the length, progress and results of any clinical trials; the introduction of competing products; the
impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals to
commercialize BiondVax's products; the difficulty in evaluating business prospects; the adequacy of available cash resource and the ability to raise capital
when needed; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; changes in the global
pharmaceutical industry; changes in customers’ budgeting priorities; European Medicines Agency and other regulatory authority approvals; natural disasters;
labor disputes; rising interest rates; general market, political or economic conditions in the countries in which we operate; pension and health insurance
liabilities; volatility or crises In the financial market; arbitration, litigation and regulatory proceedings; and war or acts of terror.

Forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. You
should not unduly rely on any forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are
reasonable, we cannot guarantee that future results, levels of activity, performance and events and circumstances reflected in the forward-looking
statements will be achieved or will occur. The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the
Securities and Exchange Commission, including our Annual Report on Form 20-F for the year ended December 31, 2017 filed with the U.S. Securities and
Exchange Commission, or SEC, which is available on the SEC’s website, www.sec.gov, and in the Company’s periodic filings with the SEC. Readers are urged to
carefully review and consider the various disclosures made in the Company’s SEC reports, which are designed to advise interested parties of the risks and
factors that may affect its business, financial condition, results of operations and prospects. These forward-looking statements speak only as of the date of
this presentation, and we assume no obligation to update or revise these forward-looking statements for any reason, whether as a result of new information,
future events or otherwise, except as required by law.

One • For All : The Universal Flu Vaccine

 3

2017 SUCCESSES DRIVE 2018 PLANS

“…We now have the resources to launch our Phase 3 program towards commercialization.” 1

Israeli government support mid-size commercial facility2 – March 30

Ministry of Economy granted 20% of a NIS 20m budget towards construction

€20 million non-dilutive co-funding3 – June 19

The European Investment Bank (EIB) signed an agreement to support commercial scale production and Phase 3

BiondVax successfully meets Phase 2b clinical trial endpoints4 – July 20

M-001 showed statistically significant elevated T-cell immune responses, good safety profile and well-tolerated

$10 million secondary offering5 – September 18

Following the placement, BiondVax has 3 large strategic investors, each holding 5% to 20%

European Medicines Agency (EMA) Allows Phase 3 Trial Plan6 – December 27

EMA Scientific Advice accepts the placebo controlled trial design, facilitating procedures towards Phase 3

1. http://www.biondvax.com/2017/06/biondvaxs-ceo-provides-first-half-2017-general-corporate-update/
2. http://www.biondvax.com/2017/03/biondvax-approved-for-grant-from-israels-ministry-of-economy-and-industry-to-build-facility-for-commercial-scale-production-of-its-universal-flu-vaccine/
3. http://www.biondvax.com/2017/06/european-investment-bank-eib-supports-late-stage-development-and-production-of-biondvaxs-universal-flu-vaccine-candidate-under-horizon-2020-initiative/
4. http://www.biondvax.com/2017/07/biondvax-reports-positive-phase-2b-clinical-trial-results-for-its-universal-flu-vaccine/
5. http://www.biondvax.com/2017/09/biondvax-announces-closing-of-10-million-public-offering-of-american-depositary-shares-and-exercise-of-over-allotment-option/
6. http://www.biondvax.com/2017/12/biondvax-plans-phase-3-clinical-trial-following-receipt-of-scientific-advice-from-the-european-medicines-agency-ema/
Flu
A serious
challenge
for public
health
 5

A SEASONAL PROBLEM… A PANDEMIC THREAT

The Flu Virus: Frequent and Unpredictable Mutations

SEASONAL FLU – DESPITE ANNUAL VACCINE PRODUCTION (500 MILLION DOSES1)

Flu cases:
Severe illness: Deaths:
up to 20%
3 – 5 million 650,0002
or 1.5 billion
❖ At-risk Seniors: 80% of deaths & most hospitalizations3
❖ High economic burden: Over $87B including $56B in elderly4
❖ USA: Up to 56,000 deaths and 710,000 hospitalizations5

PANDEMIC FLU
❖ New pandemic strain: When?… Where?... Which?
❖ Higher morbidity & mortality worldwide

1 WHO: http://www.who.int/influenza_vaccines_plan/objectives/objective2/en/ and https://en.wikipedia.org/wiki/Influenza_vaccine#Uptake; 2 WHO: http://www.who.int/news-room/detail/14-12-2017-up-

to-650-000-people-die-of-respiratory-diseases-linked-to-seasonal-flu-each-year (varies annually); 3 Vaccine journal: www.sciencedirect.com/science/article/pii/S0264410X15002315, Table 3; 4 Molinari et. al,
The annual impact of seasonal influenza in the US, Vaccine 25 (2007) 5086–5096; 5 CDC: www.cdc.gov/flu/about/disease/burden.htm
Image: Influenza victims crowd into an emergency hospital near Fort Riley, Kansas in this 1918 file photo. National Museum of Health
 6

CURRENT VACCINE FALLS SHORT: THE MISMATCH

Seasonal Flu Vaccine Effectiveness (VE)
1
CDC data , flu seasons 2004-2018
2004-05 10%

2005-06 21% Average

2006-07 52% 40% VE in
2007-08 37% general
2008-09 41% population
2009-10 56%

2010-11 60%
Why current solutions fall short… 2011-12 47%

• Past strains selection → Mismatch phenomenon 2012-13 49% As low as

2013-14 52% 9% VE
• Previous season’s vaccine will not necessarily 2014-15 19% in elderly2
protect against next season’s flu strains
2015-16 48%

• 4-6 month production lag 2016-17 40%

2017-18 36% *Interim estimate

1 Center for Disease Control: http://www.cdc.gov/flu/professionals/vaccination/effectiveness-studies.htm [Retrieved 18.Feb.2018]

2 World Health Organization: http://www.who.int/immunization/research/meetings_workshops/2a_Graham_pdvac_sept14.pdf
 7

THE ELDERLY – AT RISK AND IN NEED

• ~80% of seasonal flu related death occurs in elderly1
• Seasonal vaccine effectiveness as low as 9% for elderly2
• 86% of adults 65+ have chronic conditions3
• Influenza worsens outcomes of chronic illness
• Elderly flu cost in US estimated4 at $56B per year
(hospitalization, mortality, lost earnings)

NIH: “During the period from 1989 to 1997 the vaccination rate for
elderly persons ≥65 years of age in the US increased from 30 to 67%.
Despite this increase in coverage, mortality and hospitalization rates
continued to increase rather than decline as would be expected...”
International Journal of Epidemiology5 (Vol. 35, Issue 2, P352-353)

1 Vaccine journal: www.sciencedirect.com/science/article/pii/S0264410X15002315, Table 3; 2 WHO:

http://www.who.int/immunization/research/meetings_workshops/2a_Graham_pdvac_sept14.pdf
3 www.ncoa.org/healthy-aging/flu-you/flu-facts/; 4 Molinari et. al, The annual impact of seasonal influenza in the US, Vaccine 25 (2007)

5086–5096; 5 https://academic.oup.com/ije/article/35/2/352/694736;
 8

MEETING MILESTONES & CATALYSTS

Solid Science, Advanced Clinical Stage, Strong IP
- USA NIH Phase 2

- USA CMO Ph3 material

TASE June 2007 May 2015 June 2017
Delisted 2018 Nasdaq: BVXV €20M EIB - Mid-size manufacturing
plant construction
Technology developed
by Prof. Ruth Arnon - Pivotal Phase 3 trial
2005 2008 2010 2017 2018

Mid 90’s 1st of two 1st of four FDA accepts EMA Scientific
Phase 1/2 (IL) Phase 2 (IL, EU) IND Advice accepts
BiondVax Phase 3 trial design
Operational

Co-Inventor of The Vaccine is Safe and Immunogenic

• 698 young adult to elderly have participated in clinical trials
• The vaccine was shown to be safe and immunogenic in all studies

One • For All : The Universal Flu Vaccine

 9

M-001: A COMMON DENOMINATOR OF FLU VIRUSES

The Influenza Virus Target Common Regions
Nine common regions (epitopes) of flu strains
are connected to make one recombinant
protein called M-001 produced in E.coli
Universal Flu
Vaccine M-001’s Key Advantages
A common BiondVax’s M-001 Existing vaccines
denominator for
Universal: Broad coverage Strain specific
Seasonal & Pandemic
HemAgglutinin (HA)

Single formulation enabling

strains year-round vaccination
New vaccine every year
NucleoProtein (NP)
Matrix protein (M1)

Quick, robust year-round production Long (4-6 month)

through E.coli fermentation (6-8 weeks) production cycle
Induces cellular (CMI) and enhances
Limited vaccine
humoral (HAI priming effect) immune
effectiveness
response to flu
Shelf life up to 24 months at 2-8⁰C
Not applicable, since new
(testing is ongoing) and 6 months at
vaccine every season
~25⁰C (room temperature)

One • For All : The Universal Flu Vaccine

 10

M-001: THE UNIVERSAL FLU VACCINE

M-001’s dual mode of action potentially offers multi-season and multi-strain protection
• Flu viruses are intracellular parasites
• Most of their lifecycle occurs inside our cells, thus are out of the reach of antibodies
• Our immune system mainly fights viral infection with cellular immunity via cytokines
Our immune system has 2 arms:
Cellular (CMI) Humoral (HAI)
Works inside infected cells BiondVax’s M-001 Works outside cells
Dual Mode of Action
T-cell Directly T-cell B-cell
induces priming
e.g. T-Helper, CD4, CD8 T-Cells effect Produce
Produce anti-viral enhances Antibodies
cytokines such as B-Cell
responses
IL-2 IFN-G

Current vaccines mainly induce

only flu strain-specific antibodies

One • For All : The Universal Flu Vaccine

 11

SUCCESSFUL CLINICAL TRIALS

M-001: Safe and Immunogenic in Young Adults to Elderly
• No treatment-related severe adverse events In the clinical trials we looked
• Adverse events were mild to moderate for the intrinsic CMI M-001
• All adverse events observed were transient immunogenicity compared to
• Both cellular and humoral immunity were induced baseline and its priming effect
Total
Phase Trial Year Population (age) Status Results
Participants
1/2 BVX-002 2009 Younger Adults (18-49) 63 Completed M-001 was well
1/2 BVX-003 2010 Older Adults (55-75) 60 Completed tolerated and a
cellular (CMI) and
2 BVX-004 2011 Younger Adults (18-49) 200 Completed
humoral (priming
2 BVX-005 2012 Elderly (65+) 120 Completed
effect) immune
2 BVX-006 2015 Older Adults (50-65) 36 Completed response was
2b BVX-007* 2015-16 EU Adults (18-60) 219 Completed observed
698

2 BVX-008 2018 USA Adults (18-49) 120 NIH: 1st participant enrolled April 2018
3 BVX-010 2018 E. European Adults (50+) 9,630 In preparation

*One • For
BVX-007 Allconducted
was : The Universal Fluwith
in collaboration Vaccine
the EU’s UNISEC consortium
 12

M-001: INDUCES CELL MEDIATED IMMUNITY

Direct Evidence: CD8, CD4 T-cell Activated Cells Produce TH1 Cytokines (IFN-gamma, IL-2 & TNF-alpha)
BVX0051: CD4 & IFN-gamma in Elderly BVX0051: CD8 & IFN-gamma in Elderly
0.3 0.3 * M-001 twice Day 0 *
M-001 twice Day 0

% positive cells (Mean + SE)

% positive cells (Mean + SE)

0.25
** 0.25
M-001 twice Day 42
* * M-001 twice Day 42
0.2 0.2

0.15 * * 0.15

0.1 0.1

0.05 0.05 * P<0.05

**P<0.07
0 0
A/Brisbane/10/07 A/California/7/09 A/Perth/16/09 B/Brisbane/60/08 Flumist 2011 A/Brisbane/10/07 A/California/7/09 A/Perth/16/09 B/Brisbane/60/08 Flumist
H3N2 H1N1 H3N2 H3N2 H1N1 H3N2

UNISEC (EU): statistically significant anti viral cytokines UNISEC (EU): 13 fold increase in responders expressing 2 cytokines (18-60 Y)
1000 1400 *
* P<0.05 “Multiple-Cytokine-
1200 1347
800 Producing Antiviral CD4
% over placebo

* % over placebo 1000

678
600 *
530 800 *
T Cells Are Functionally
474 600 663 Superior to Single-
400 380
211 *
200
400
* 134 347
Cytokine-Producing
* 38 200
0
-23 0 Cells”
0 S Kannanganat et al, J VIROL, 2007,
M-001: high
1mgINF low INF highIL2
0.5mg 1mg low il2 1mg
0.5mg high low tnfa
0.5mg M-001:
-200 high low
1mg 0.5mg high
1mg low 2/3 1mg
0.5mg high 0.5mg
low 81(16)8468–76
-200
tnfa any any 2/3 combi combi
IFN-gamma IL-2 TNF-alpha Single Double Triple

1Jacob Atsmon et al. Priming by a novel universal influenza vaccine (Multimeric-001)—A gateway for improving immune response in the
elderly population. Vaccine 32 (2014) 5816–5823
 13

M-001: ENHANCES HUMORAL IMMUNITY

Indirect Evidence: Extending T-Cell Priming Effect for Enhanced HAI Responses to Current Flu Vaccines
BVX0051: 2011/12, age 65+ YO
70
*
“M-001 can provide broadened enhanced immunity
60 TIV Twice M-001 + TIV extending even to influenza strains destined to
% Seroconversion

50
40
circulate in future years.” – Vaccine 2
30
20
70
10 In 2011 we *
0 administered M-001 60

% Seroprotection (HAI)
A/California/7/09 A/Perth/16/09 B/Brisbane/60/08
H1N1 pandemic swine flu to seniors 65+ 50

BVX003: 2009, age 55-75 YO

(BVX005)
40
80 TIV Twice M-001 + TIV
70
4 years later, 5 times 30
more seniors were
% seroconversion

60
20
50 seroprotected from a
40 new epidemic strain 10
30
(A/Swiss) that didn’t 0
20
10 exist in 2011! TIV 2011/12 M-001 & TIV 2011/12

0
A/Brisbane/59/07 A/Brisbane/10/07 B/Brisbane/60/08 * P<0.05
1. Jacob Atsmon et al. Priming by a novel universal influenza vaccine (Multimeric-001)—A gateway for improving immune response in the
elderly population. Vaccine 32 (2014) 5816–5823
2. Lowell GH et al. Back to the future: Immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune
responses against 2014/15 epidemic strain. Vaccine (2017)
 14

PIVOTAL CLINICAL EFFICACY PHASE 3 DESIGN

Study objective: Protection from the flu (absolute efficacy)
Study title: A pivotal multicenter, randomized, modified double-blind, placebo-controlled phase 3 trial to assess
the safety and clinical efficacy of M-001 influenza vaccine administered IM twice in old adults and elderly

Trial Design Season 1 Season 2 Season 3 (optional)

Day 1 Day 21 Day 202 Follow up Follow up

Experimental 1mg M-001 1mg M-001 Safety, RT-PCR RT-PCR or

RT-PCR or culture on
or culture on culture on any
any ILI
Control Placebo Placebo any ILI ILI
(flu season)
(flu season) (flu season)

• Population: 9,630 participants aged 50+, half 65+ years old, first cohort enrollment expected autumn 2018
• Primary Endpoints: Safety & clinical efficacy by reduction of illness rate
• Secondary Endpoints: Reduced severity of influenza illness; Lot-to-lot consistency of three M-001 batches

One • For All : The Universal Flu Vaccine

 15

PRODUCTS NEED PRODUCTION

Goal: Fully Integrated Pharma Operating Under International GMP Standards
• From pilot GMP to mid-size GMP manufacturing facility (Israel)*
• Funding: EIB, BiondVax, and Israel’s Ministry of Economy & Industry
• Capacity: up to 20 million single-doses or 40 million doses (bulk) per year
• Year-round production & stockpile per market demand

* BiondVax is collaborating with a US-based contract manufacturer

organization (CMO) for upscaling and optimization

BIONDVAX: FIRST-IN-CLASS, BEST-IN-CLASS
Player Technology
Synthetic protein
B- & T-cell peptides
(HA, M1, NP)
+ 2016: Seek created Imutex with hVIVO
4 T-cell peptides adjuvanted
formulation
Adenovirus vector expressing
• T-cell boost when
Influenza A conserved NP
and M1 proteins
Single replication virus,
M2SR; Broadening
immunogenicity to flu sub
type H3N2
Broad seasonal and
pandemic candidate. T-cell
booster
Type-specific (H1) synthetic
DNA antigens
Academic labs Stem-only immunogens
based on rational design;
DNA vaccines
One • For All : The Universal Flu Vaccine
Strength
• Broad coverage
• Six completed human clinical
trials
• Young to elderly
• Small challenge and
immunogenicity trials
administered with TIV
• First in human results
reported 2018
• Immunogenic in mice
• Intranasal, replication
deficient adenovirus
• Broad H1 antibody
responses
• Innovative approach,
heterosubtypic protection in
mice, ferrets, primates
16
Phase
Pre- Status
I II III
clinical
Statistically significant European Ph2b trial
UNISEC consortium. NIAID/NIH sponsored
N=698 ongoing collaboration Phase 2 in USA.
Preparing for Phase 3 in the EU.
N=203 2018: Phase 2b challenge, NIH collaboration
and UNISEC Phase 2b results pending.
Preparing for Ph2 in 2000 participants. Oxford
N=150 University spinoff, raised $27m in 2017
Raised $27m, including $5.5m Aug 2017
N=96 Human challenge planned Q2 2018
Formerly ITS then Vaxin. Merged
N=49 PharmaAthene, listed on NASDAQ. Phase 2
results expected 2018.
Successful ferret challenge study (January
2018)
Results in animals
 17

SUMMARY FINANCIAL DATA

Financial Data Highlights
• Lean structure with 14 employees, current operating burn
~$250K/month (excl. clinical phase 3 trial and facility construction)
• 6.5M outstanding ADS (8.7M fully diluted)
• Clinical studies sponsored by 3rd parties (UNISEC, NIH/NIAID)
• $5.5M royalty-based liabilities from OCS grants (Office of the Israeli
Chief Scientist grants, off balance sheet) American Depository Shares ticker:

• Voluntarily delisted from Tel Aviv Stock Exchange January 22, 2018.
(ADS-Shares 1:40 ratio)
BVXV
Balance Sheet Highlights (Q4 2017) BVXVW
• $21M cash on hand, no debt (~$48M invested to date)
• €20M EIB non-dilutive co-funding agreement1 signed June 2017
• Secondary offering Sept 2017, $10M gross proceeds

1 European Investment Bank (EIB) €20M support for M-001 Phase 3 trials and commercial production also includes:
• Zero-percent fixed interest loan for five years after each of the 3 drawdowns
• Variable remuneration based on royalties of net sales
• Milestone based drawdowns. Ultimate milestone includes regulatory authorization to launch Phase 3 trial
 18

FLU VACCINES – A LARGE AND GROWING MARKET

Global Flu Vaccine Sales - 2017 Flu Vaccine Market
Seasonal Flu
Others o Worldwide: ~$4.3B global market in 20161;
~$0.53B1 $0.60B5 expected to grow to $5.9B1,2 by 2021
2% 12% 13% o US: $1.6B in 2015 growing to $2.6B by 20221;
$0.08B8 ~175M doses/year1
o Forecasted CAGR of >7%2

35% 38% Pandemic Flu

o Swine Flu (A/H1N1) 2009 + first half of 2010
sales: ~$6.4B worldwide by Novartis, GSK and
Sanofi (on top of seasonal flu vaccine sales)3
$1.59B7
“…part of the national strategy for pandemic
2014/5: CSL bought
Novartis’ Flu vaccine unit,
$1.72B6 influenza, the United States’ plan is to stockpile
rebranded to Seqirus 2017: Acquired Protein enough pre-pandemic influenza vaccines to cover 20
Sciences for $750M
million in the critical workforce.”4
“The United States has spent approximately $1 billion
in these [H5N1 flu vaccine stockpile] efforts to date.”4

(1) We assume 6.35% CAGR from $4B in 2015 http://www.cnbc.com/2015/10/19/the-16-billion-business-of-flu.html (2) Technavio: 27Jan2018, Source: http://bit.ly/2DJ6Mlv (3) http://www.reports-research.com/news/datamonitor-
vaccine-market-overview-2010.html [Accessed 20 Nov 2016] (4) http://www.who.int/immunization/sage/meetings/2013/november/SAGE_WG_H5vaccine_background_paper_16Oct2013_v4.pdf (5) https://www.gsk.com/media/4629/fy-
2017-results-announcement.pdf [At exchange rate 1.24] (6) https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q4-results-2017/ [At exchange rate 1.08] (7) http://annualreport.csl.com.au/year-in-
review/business-highlights.htm (8) https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20announcement%20.pdf
 19

MANAGEMENT

Ron Babecoff Tamar Ben-Yedidia Uri Ben-Or Shimon Hassin Joshua Phillipson
DMV, MEI PhD CPA, MBA PhD Hon. BSc

Founder,
President & CEO
•Degree from University of Liège • Co-inventor of the universal
(ULG)
•Master in Entrepreneurship &
Innovation (ISEMI, Swinburne)
•Omrix Biopharmaceuticals Ltd
(Marketing Manager)
•Dexcel Pharma (Regional Export
Manager)
CSO
flu vaccine
• Degree from Weizmann
Institute of Science
• Biotechnology General Ltd.
CFO
• Degree from College of
Administration
• Glycominds Ltd. (VP Finance)
• Menorah Capital Markets
(Comptroller)
COO BD
• Degree from University of • Hon. BSc. from University of
Maryland Biotechnology Toronto
Institute • Accenture (Business
• Kadimastem (CEO) Management Consultant)
• InSight Biopharmaceuticals • BioData Ltd. (Marketing
(Head of Bioprocessing) Manager)

One • For All : The Universal Flu Vaccine


BOARD OF DIRECTORS
Prof. Avner Rotman, PhD
Chairman of the Board
Dr. George Lowell, MD
Director
Ron Babecoff, DMV, MEI
Founder, President and CEO
Mr. Isaac Devash, MBA
Director
Mrs. Michal Marom Brikman, CPA
Director
Dr. Ruth Ben Yakar, PhD
Director
Dr. Morris C. Laster, MD
Director
One • For All : The Universal Flu Vaccine
20
Biodar (CEO), Rodar (Founder), Israel Biotech Organization (Chairman,
Steering committee)
ID Biomedical (CSO), Intellivax (Founder), Walter Reed General Hospital
(Consultant)
Omrix Pharmaceuticals Ltd (Marketing Manager), Dexcel Pharma
Technologies Ltd. (Formerly Dexxon, Regional Export Manager))
Credit Suisse First Boston (Investment Banking), Private equity and venture
capital funds (Founder)
Linkury Technology International Group (CFO), Union Bank, Spectronix,
Biomedix incubator, ADO group, Arko holdings, Algomizer (Director)
BioSight Ltd (CEO, Director), SHL Telemedicine (Director), Cellect
Biotechnology (Director)
BioLineRx (CEO, Director), OurCrowd (Partner), Clil Medical (CEO), Vital
Spark (CEO), Kitov Pharmaceuticals (Co-founder, Director)
 21

CAP TABLE

Exercise
Nasdaq: BVXV ADS ADS Expiration
31 Dec 2017 Outstanding
% price
Equivalent Date
NIS ($)
Ordinary ADS 6,535,490 75.18%

NIS 0.70 Employees

Options 329,457 3.79% $ 7.20
($ 0.18) Variable

ADS Warrants 1,762,897 20.28% $ 6.25 May 5, 2020

Warrants issued to
65,425 0.75% $ 6.25 May 11, 2020
underwriters
Fully Diluted
Shares 8,693,269 100.00%
Outstanding

Voluntarily delisted from Tel Aviv Stock Exchange January 22, 2018. (ADS-Shares 1:40 ratio)

One • For All : The Universal Flu Vaccine

 22

IP: COMPREHENSIVE AND EXPANDING COVERAGE

Title International Priority &
Subject Matter Status Expiry
(updated: Apr. 26, 2018) Publication Assignee
11/30/1998
Vaccine comprising Granted: Australia, Belgium, Canada, France, Germany, Hong Nov 2019
Peptide-Based Vaccine for Yeda R&D
WO 00/032228 different epitopes Kong, Israel, Italy, Korea, Mexico, Netherlands, New Zealand, (Aug 2020
Influenza licensed to
of the virus Spain, Switzerland, UK, USA for US)
BiondVax
Wide–range 12/6/2005
vaccines – broad Granted: Australia, Austria, Belgium, Canada, Denmark, France, Dec 2026
Improved Influenza Yeda R&D
WO 2007/066334 strain and Germany, Greece, Ireland, Israel, Italy, Luxembourg, Netherlands, (Jan 2027
Vaccine licensed to
extended Portugal, Spain, Sweden, Switzerland, UK, USA for US)
protection BiondVax

Granted: Australia, Austria, Belgium, Canada, China, Croatia,

Vaccines Czech Republic, Denmark, Finland, France, Germany, Hong Kong,
comprising multiple Aug 2028
Multimeric Multi-Epitope 8/2/2007 Hungary, India, Ireland, Israel, Italy, Japan, Korea, Luxembourg,
WO 2009/016639 copies of several (Aug 2031
Influenza Vaccines BiondVax Mexico, Netherlands, Poland, Portugal, Romania, Russia, Spain,
epitopes – current for US)
product Sweden, Switzerland, Turkey, UK, USA
Filed: Brazil
Multimeric Multi-Epitope Use of Multimeric
Polypeptides in improved as a primer to Granted: Australia, USA
WO 2012/114323 BiondVax Feb 2031
Seasonal and Pandemic conventional Under Examination: Canada
Influenza Vaccines vaccines

Vaccine Compositions of Filed: Australia, Canada, China, Europe, Hong Kong, India, Israel,
Multimeric Multi-epitope Production & 4/3/2014
WO 2015/151103 Japan April 2035
Influenza Polypeptides formulation BiondVax
and their Production Under Examination: USA

One • For All : The Universal Flu Vaccine

The Universal
Flu Vaccine
Multi-Season
Multi-Strain
Flu Vaccine
CONTACT INFORMATION:
JOSHUA PHILLIPSON
j.phillipson@biondvax.com
+972-8-930-2529
www.biondvax.com